{"id":"W4311018682","doi":"10.1200/jco.22.01065","title":"Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Cilag; NIHR Cambridge Biomedical Research Centre; Genentech; National Institutes of Health; Ipsen; MorphoSys; Astellas Pharma; Eisai; National Institute for Health and Care Research; Cancer Research UK; Merck KGaA; ECOG-ACRIN Cancer Research Group; BeiGene; Medical Research Council; Les Laboratories Pierre Fabre; TG Therapeutics; Daiichi-Sankyo; Celldex Therapeutics; Celgene; NRG Oncology; American College of Radiology Imaging Network; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Oncosuisse; GlaxoSmithKline; National Cancer Research Institute; National Health and Medical Research Council; EUSA Pharma; Cancer Research Institute; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer; Plexxikon; Relay Therapeutics; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Amgen; Breast Cancer Research Foundation; Sanofi","keywords":"Exemestane; Tamoxifen; Medicine; Breast cancer; Hazard ratio; Oncology; Internal medicine; Gynecology; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00171819,0.0001281397,0.0006162124,0.00005757608,0.00005567342,0.000006051258,0.0003279562,0.0002250934,0.0001495859],"category_scores_gemma":[0.0004124176,0.00009906964,0.0002322414,0.00008067139,0.00009006614,0.000005564493,0.0001737911,0.001027796,0.00000415075],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007020191,"about_ca_system_score_gemma":0.0009214431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001852719,"about_ca_topic_score_gemma":0.00007332295,"domain_scores_codex":[0.9970573,0.0007844826,0.001417941,0.0002566265,0.0002442073,0.0002394979],"domain_scores_gemma":[0.9982424,0.0003404607,0.0009529975,0.0001955836,0.00009996463,0.0001685703],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.09089021,0.004654021,0.1304578,0.000007262708,0.0013569,0.001797216,0.0001957206,0.00310892,0.1977464,0.00003786294,0.03688966,0.5328581],"study_design_scores_gemma":[0.04916534,0.0462678,0.3387601,0.00004887075,0.0001540362,0.0008841535,0.0002632431,0.0001868518,0.0092676,0.0003931815,0.5541329,0.0004759102],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916418,0.002855649,0.000008281078,0.003112456,0.001371114,0.0001280595,0.0001169098,0.000003740872,0.0007620183],"genre_scores_gemma":[0.9916604,0.00551497,0.0003101144,0.0009268044,0.001313138,0.00001001721,0.00003731249,0.00001828869,0.0002089501],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5323822,"threshold_uncertainty_score":0.4465317,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04385691293835649,"score_gpt":0.389506704370043,"score_spread":0.3456497914316865,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}